COMP <GO>
ALKS vs JNJ // PIOTROSKI F-SCORE QUALITY
Alkermes plc (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ALKS 5
— JNJ 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $45.34 (-0.07%) • MKT CAP: $7.61B
piotroski-score
7/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALKS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALKS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.70% | 67.90% | +18.80 | ALKS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.00% | 25.50% | -11.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.1x | 18.5x | +6.60 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 6.31% | 2.97% | +3.34 | ALKS | /fcf-yield <GO> |
| Operating Margin | 17.20% | 34.70% | -17.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 16.40% | 28.50% | -12.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -5.20% | 6.00% | -11.20 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.03 | 5.59 | +2.44 | ALKS | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | ALKS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.1 | 60.4 | +0.78 | ALKS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.08 | -0.03 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.3x | 23.0x | +6.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.61B | $662.49B | -$654.88B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALKS REV | JNJ REV | ALKS GROSS % | JNJ GROSS % | ALKS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.48B | $94.19B | 86.7% | 67.9% | $480.3M | $19.70B |
| FY 2024 | $1.56B | $88.82B | 84.2% | 69.1% | $405.6M | $19.84B |
| FY 2023 | $1.66B | $85.16B | 44.0% | 44.0% | $326.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALKS // BETA 1.05
JNJ // BETA 1.08